Abeomics
Pre-clinicalABEOMICS provides Recombinant Biosimilar Antibodies Trastuzumab, Efalizumab, Mogamulizumab and many more..
Founded
2005
Focus
AntibodiesDiagnostics
About
ABEOMICS provides Recombinant Biosimilar Antibodies Trastuzumab, Efalizumab, Mogamulizumab and many more..
Funding History
1Total raised: $2.5M
Seed$2.5MUndisclosedJun 15, 2018
Company Info
TypePrivate
Founded2005
LocationSan Diego, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile